Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
61,576.37 +2,569.50 (+4.35%) CMC Crypto 200
1,337.33 +60.35 (+4.72%)
Daiichi Sankyo Company, Limited (DSNKY)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 12:36PM EDT. Market open.
| Previous close | 35.48 |
| Open | 36.84 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 35.49 - 36.84 |
| 52-week range | 23.72 - 37.57 |
| Volume | |
| Avg. volume | 178,054 |
| Market cap | 68.551B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 54.17 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.24 (0.69%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
© 2024 Yahoo. All rights reserved.